Trial Profile
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Multiple system atrophy; Orthostatic hypotension
- Focus Therapeutic Use
- 11 Oct 2021 Status changed from recruiting to completed.
- 21 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
- 21 Dec 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Mar 2021.